7 stories found
Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a strategic collaboration to co-develop novel radiopharmaceutical therapies, combining their expertise in oncology and drug development.
An article examines the investment potential of Regeneron Pharmaceuticals, Inc. (REGN) for prospective stock purchasers.
Analysts are offering their latest comments and assessments regarding Regeneron Pharmaceuticals (REGN).
Biotechnology company Regeneron Pharmaceuticals expects to incur approximately $102 million in pre-tax in-process research and development charges for the first quarter.
Several financial firms have issued new ratings, price targets, or coverage initiations for biotech and pharmaceutical companies including Beam Therapeutics, Krystal Biotech, 4D Molecular Therapeutics, BioMarin Pharmaceutical, Vertex Pharmaceuticals, CRISPR Therapeutics AG, Regeneron Pharmaceuticals, and UniQure.
Piper Sandler has upgraded Regeneron Pharmaceuticals to an 'overweight' rating, citing strong performance from its drug Dupixent and the potential of its robust pipeline.
An analysis questions whether Regeneron Pharmaceuticals stock is underperforming relative to the broader Nasdaq index.